About the Myeloma Academy Nursing Best Practice Guides

This document explains the aims of the Myeloma UK Nursing Best Practice Guides and how they should be used to enhance knowledge and inform nursing practice thus enabling nurses to deliver the highest possible treatment, care and support to myeloma patients and their families.



Phase II trial of BI-505 in myeloma terminated

The Swedish biotechnology company, BioInvent, has announced it has terminated a Phase I/ II trial of its lead drug BI-505 as a treatment in conjunction with high-dose therapy and stem cell transplantation (HDT-SCT) for newly diagnosed myeloma patients. This follows the verbal notice issued in November 2016 by the US Food and Drug Administration (FDA)…